GLPwatch
Papers (12034)
Page 92 of 201, ranked by citation count.
- A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease.
- Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
- Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.
- Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients.
- Liraglutide ameliorates COCl2-induced oxidative stress and apoptosis in H9C2 cells via regulating cell autophagy.
- Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation.
- Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?
- Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model.
- Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.
- A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity.
- Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.
- Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.
- Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice.
- Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.
- Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression.
- Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.
- Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals.
- Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus.
- Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.
- National trends in prescription drug expenditures and projections for 2025.
- Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
- Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy.
- A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
- Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy.
- Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment.
- Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity-Reply.
- Glucagon-like peptide-1 receptor controls exocytosis in chromaffin cells by increasing full-fusion events.
- Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).
- Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.
- Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis.
- Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
- Impact of Glucagon-like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients.
- Effects of Exendin-4 on pancreatic islets function in treating hyperglycemia post severe scald injury in rats.
- A new approach to disease-modifying drug trials in Parkinson's disease.
- Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy.
- Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.
- Semaglutide and effective weight control.
- An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.
- Nutrient Optimization Reduces Phosphorylation and Hydroxylation Level on an Fc-Fusion Protein in a CHO Fed-Batch Process.
- Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.
- Hypothalamic GABAergic Neurons Expressing Cellular Retinoic Acid Binding Protein 1 (CRABP1) Are Sensitive to Metabolic Status and Liraglutide in Male Mice.
- Liraglutide promotes UCP1 expression and lipolysis of adipocytes by promoting the secretion of irisin from skeletal muscle cells.
- Exendin-4 promotes proliferation of adipose-derived stem cells through ERK and JNK signaling pathways.
- Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights.
- GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
- Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.
- Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.
- Evaluating the safety profile of semaglutide: an updated meta-analysis.
- A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease.
- Dulaglutide mitigates high dietary fructose-induced renal fibrosis in rats through suppressing epithelial-mesenchymal transition mediated by GSK-3β/TGF-β1/Smad3 signaling pathways.
- Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome.
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
- Semaglutide, suicidal ideation and behaviour: A resting state functional magnetic resonance imaging perspective.
- Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
- Semaglutide: a promising new glucagon-like peptide-1 receptor agonist.
- Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
- Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
- Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).
- Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys<sup>40</sup>(AhxHYNIC-[<sup>99m</sup>Tc]/EDDA)NH<sub>2</sub>]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma.